- A syndicate of global healthcare investors, including RTW Investments, SR One Capital Management (SR One), TCG Crossover (TCGX), RA Capital Management, HBM Healthcare Investments, and SymBiosis, participated in the Series D1 financing.
- The funds are anticipated to propel CX11, an oral small molecule GLP-1 receptor agonist (RA), through current U.S. and upcoming global Phase 2 studies, as well as other cardiometabolic initiatives.
BERKELEY HEIGHTS, N.J., Jan. 22, 2026 — Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical firm focused on creating novel treatments for global cardiometabolic disease patients, today reported the finalization of its Series D1 financing, securing up to $287 million . The capital raised is intended to fund the progress of CX11, a distinct oral small molecule GLP-1 RA for obesity and overweight individuals, which is now in a CORXEL-run U.S. Phase 2 trial and a Vincentage-conducted Phase 3 trial in China. It will also support other cardiometabolic projects targeting conditions like acute ischemic stroke and hypertension.
New investors in the round comprised SR One, TCGX, RA Capital Management, HBM Healthcare Investments, SymBiosis, Adage Capital Management, Invus, SilverArc Capital, and several others. Current investors RTW Investments and Hengdian Group Capital also took part, reinforcing their ongoing belief in CX11’s unique clinical profile, CORXEL’s operational effectiveness in clinical trials, and the firm’s strategic vision.
The financing proceeds are allocated for the following purposes:
- Progress the flagship program, CX11, via its current U.S. Phase 2 trial for obesity and overweight, its intended global Phase 2 trial for Type 2 Diabetes Mellitus (T2DM), and early groundwork for CX11’s Phase 3 trials;
- Move forward the company’s other programs in clinical development; and
- Enhance the company’s worldwide operational and development infrastructure to facilitate global, multiregional clinical trials.
“This financing round marks a pivotal moment for CORXEL since its inception, providing the resources to hasten the worldwide development of best-in-class cardiometabolic treatments and launching the company into a new phase of expansion,” stated Sandy Mou, Board Executive Director and Chief Executive Officer of CORXEL. “We appreciate the trust from both our longstanding and new investors in CORXEL’s prospects, and our determination to elevate CORXEL into a major global biopharmaceutical entity has never been greater.”
“RTW is dedicated to enabling the next wave of scientific and medical innovations to improve lives,” said Roderick Wong, Managing Partner and Chief Investment Officer at RTW Investment. “In our view, CORXEL’s clinical advancements, rigorous execution, and veteran leadership team set the stage for key near-term milestones and enduring value generation. We are thrilled to back their path to becoming a frontrunner in cardiometabolic disorder biotech.”
As part of the financing agreement, SR One, TCGX, and some other investors will gain the right to designate 3 new members to CORXEL’s Board of Directors.
About CORXEL
CORXEL is a clinical-stage biopharmaceutical company committed to pioneering innovative therapies for cardiometabolic condition patients worldwide. The company is guided by a seasoned management team with a proven history of sourcing, licensing, and advancing promising clinical candidates aimed at established targets with confirmed mechanisms of action (MoAs). CORXEL’s varied pipeline of clinical-stage candidates could set new treatment benchmarks and overcome major shortcomings of existing therapies for numerous cardiometabolic indications. The company is working on selective small molecule compounds across cardiometabolic diseases, featuring lead candidate CX11, an oral GLP-1 RA for obesity, overweight, and T2DM; JX10, a thrombolytic and anti-inflammatory drug for acute ischemic stroke; and JX09, a highly selective aldosterone synthase inhibitor for hypertension. CORXEL also has other small molecule projects in development aimed at validated obesity targets.
For further information about CORXEL, please visit www.corxelbio.com
Contact: media@corxelbio.com
